Man Group plc Raises Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Man Group plc grew its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 342.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 121,792 shares of the company's stock after acquiring an additional 94,263 shares during the quarter. Man Group plc's holdings in Amneal Pharmaceuticals were worth $965,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. MetLife Investment Management LLC boosted its position in shares of Amneal Pharmaceuticals by 2.5% during the 4th quarter. MetLife Investment Management LLC now owns 94,639 shares of the company's stock valued at $750,000 after acquiring an additional 2,297 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Amneal Pharmaceuticals by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 90,460 shares of the company's stock worth $716,000 after buying an additional 2,911 shares during the last quarter. Arizona State Retirement System lifted its position in Amneal Pharmaceuticals by 13.6% in the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company's stock worth $320,000 after buying an additional 4,851 shares during the last quarter. Alliancebernstein L.P. lifted its position in Amneal Pharmaceuticals by 2.5% in the fourth quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock worth $1,586,000 after buying an additional 4,927 shares during the last quarter. Finally, Globeflex Capital L P lifted its position in Amneal Pharmaceuticals by 3.8% in the fourth quarter. Globeflex Capital L P now owns 144,439 shares of the company's stock worth $1,144,000 after buying an additional 5,245 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Insider Activity

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33% decrease in their position. The disclosure for this sale can be found here. Insiders own 17.45% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays raised their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Finally, Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $11.50.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX traded up $0.01 on Thursday, hitting $7.22. 228,526 shares of the company's stock were exchanged, compared to its average volume of 1,441,541. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.29 and a 12 month high of $9.48. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -10.61 and a beta of 1.17. The business's 50 day simple moving average is $7.53 and its two-hundred day simple moving average is $8.03.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.14 by $0.05. The firm had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.